4b7i
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='4b7i' size='340' side='right'caption='[[4b7i]], [[Resolution|resolution]] 2.36Å' scene=''> | <StructureSection load='4b7i' size='340' side='right'caption='[[4b7i]], [[Resolution|resolution]] 2.36Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[4b7i]] is a 2 chain structure | + | <table><tr><td colspan='2'>[[4b7i]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4B7I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4B7I FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1aj7|1aj7]], [[1aqk|1aqk]], [[1bey|1bey]], [[1d5b|1d5b]], [[1d5i|1d5i]], [[1d6v|1d6v]], [[1dn2|1dn2]], [[1e4k|1e4k]], [[1fc1|1fc1]], [[1fc2|1fc2]], [[1fcc|1fcc]], [[1h3t|1h3t]], [[1h3u|1h3u]], [[1h3v|1h3v]], [[1h3w|1h3w]], [[1h3y|1h3y]], [[1i7z|1i7z]], [[1l6x|1l6x]], [[1oqx|1oqx]], [[1t83|1t83]], [[1t89|1t89]], [[2iwg|2iwg]], [[2j6e|2j6e]], [[2rcs|2rcs]], [[2wah|2wah]], [[4acp|4acp]]</td></tr> | + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1aj7|1aj7]], [[1aqk|1aqk]], [[1bey|1bey]], [[1d5b|1d5b]], [[1d5i|1d5i]], [[1d6v|1d6v]], [[1dn2|1dn2]], [[1e4k|1e4k]], [[1fc1|1fc1]], [[1fc2|1fc2]], [[1fcc|1fcc]], [[1h3t|1h3t]], [[1h3u|1h3u]], [[1h3v|1h3v]], [[1h3w|1h3w]], [[1h3y|1h3y]], [[1i7z|1i7z]], [[1l6x|1l6x]], [[1oqx|1oqx]], [[1t83|1t83]], [[1t89|1t89]], [[2iwg|2iwg]], [[2j6e|2j6e]], [[2rcs|2rcs]], [[2wah|2wah]], [[4acp|4acp]]</div></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4b7i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4b7i OCA], [https://pdbe.org/4b7i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4b7i RCSB], [https://www.ebi.ac.uk/pdbsum/4b7i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4b7i ProSAT]</span></td></tr> |
</table> | </table> | ||
== Disease == | == Disease == | ||
- | [[ | + | [[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[https://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4. |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 23: | Line 23: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: Human]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Aricescu, A R]] | [[Category: Aricescu, A R]] |
Revision as of 07:02, 31 August 2022
Crystal Structure of Human IgG Fc Bearing Hybrid-type Glycans
|
Categories: Large Structures | Aricescu, A R | Baruah, K | Bowden, T A | Coles, C H | Crispin, M | Harvey, D J | Jones, E Y | Scanlan, C N | Song, B D | Stuart, D I | Antibody | Hybrid | Igg | Immune system | Swainsonine